Should New Cancer Research Tools Require Action From Twist Bioscience (TWST) Investors?

Simply Wall St.11-05

Twist Bioscience recently introduced Twist MRD Express and Twist Express Screening Antibodies, expanding its synthetic DNA and protein tools for cancer research and antibody discovery with rapid, high...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681754110?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","is_english":true,"pubTime":"2026-11-05 21:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681754110","market":"hk","top_or_hot":-1,"title":"Should New Cancer Research Tools Require Action From Twist Bioscience (TWST) Investors?","media":"Simply Wall St.","content":"<div>\n<p>Twist Bioscience recently introduced Twist MRD Express and Twist Express Screening Antibodies, expanding its synthetic DNA and protein tools for cancer research and antibody discovery with rapid, high...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/should-new-cancer-research-tools-require-action-from-twist-b\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should New Cancer Research Tools Require Action From Twist Bioscience (TWST) Investors?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould New Cancer Research Tools Require Action From Twist Bioscience (TWST) Investors?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-05 21:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/should-new-cancer-research-tools-require-action-from-twist-b><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Twist Bioscience recently introduced Twist MRD Express and Twist Express Screening Antibodies, expanding its synthetic DNA and protein tools for cancer research and antibody discovery with rapid, high...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/should-new-cancer-research-tools-require-action-from-twist-b\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/should-new-cancer-research-tools-require-action-from-twist-b","article_id":"2681754110","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-twst/twist-bioscience/news/should-new-cancer-research-tools-require-action-from-twist-b","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681754110","pubTimestamp":1793885265,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 5, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp","IDNA":"iShares Genomics Immunology and Healthcare ETF","GNOM":"Global X Genomics & Biotechnology ETF","BK4211":"区域性银行","ISBC":"投资者银行","BK4588":"碎股","WDNA":"WisdomTree BioRevolution Fund","BK4585":"ETF&股票定投概念","ARKG":"ARK Genomic Revolution ETF","BK4139":"生物科技"},"translate_title":"新的癌症研究工具是否需要 Twist Bioscience (TWST) 投资者采取行动？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WDNA":0.6,"TWST":1.5,"GNOM":0.6,"ISBC":1.5,"ARKG":0.6,"IDNA":0.6},"content_text":"Twist Bioscience recently introduced Twist MRD Express and Twist Express Screening Antibodies, expanding its synthetic DNA and protein tools for cancer research and antibody discovery with rapid, high throughput custom production. The new offerings aim to shorten development timelines for liquid biopsy, MRD assays and antibody screening, which could influence demand patterns, capacity use and future product mix across Twist Bioscience’s broader portfolio. We will look at how Twist Bioscience's investment narrative is shaped by Twist MRD Express and its focus on faster personalized oncology tools.  Scan other cancer research suppliers moving quickly on high throughput tools by checking out the 38 healthcare AI stocks alongside Twist Bioscience’s latest MRD and antibody launches. AdvertisementTwist Bioscience Investment Narrative Recap To own Twist Bioscience, you need to believe its high-throughput DNA and protein platform can turn strong product interest into a larger, more diverse customer base while gradually shrinking operating losses. The recent MRD Express and antibody launches support that thesis on paper, but the immediate impact on revenue mix and margins is hard to quantify in the near term. The key near term catalyst remains Twist Bioscience’s push toward adjusted EBITDA breakeven, helped by gross margins already above 50%. The biggest risk stays the same. The firm is still loss making, with heavy reliance on a small pool of large NGS customers and a share price that has already moved sharply. The Twist MRD Express launch is the clearest operational tie to those catalysts. It leans on the existing silicon DNA platform, offering up to 10,000 custom probes, rapid turnaround and design support. That kind of scale can matter if liquid biopsy and MRD researchers standardize on Twist workflows for recurrent testing. This product also sits squarely against current risks. Execution missteps could limit adoption, which matters when revenue concentration is high and the stock trades on a rich P/S multiple. For you as a shareholder, the central question is whether MRD Express can help Twist Bioscience convert new assays into durable, higher margin demand without needing fresh capital. Twist Bioscience is tied to a consensus narrative that points to US$746.7 million in revenue and US$118.8 million in earnings by 2029, built on analyst assumptions of 20.0% yearly revenue growth and a swing in earnings of about US$255.5 million from a loss of US$136.7 million today. Uncover why Twist Bioscience's fair value indicates an 18% potential upside to its current price that could narrow quickly. NasdaqGS:TWST 1-Year Stock Price Chart Exploring Other Perspectives One of the biggest swing factors in the alternate Twist Bioscience story is how far AI driven demand could stretch future capacity. The most optimistic analysts were already modeling revenue of about US$840.7 million and earnings of US$31.6 million by 2029 before MRD Express arrived. That is a very different script from consensus, so treat this launch as a prompt to compare those scenarios yourself. Explore 3 other Twist Bioscience fair value estimates, including one that suggests potential upside of up to 135% from the current price. The Verdict Is Yours Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own analysis and judgment.  A great starting point for your Twist Bioscience research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision. See our latest analysis for Twist Bioscience. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Twist Bioscience's overall financial health at a glance.  Looking For More Investment Ideas Beyond Twist Bioscience? If Twist Bioscience has you thinking about where asymmetric opportunities might sit next, it can help to line it up against a broader watchlist. The Simply Wall St Screener lets you filter by balance sheet strength, income potential or valuation so you can build a set of candidates that actually fits your risk tolerance.  If capital preservation matters most, start with companies that pair resilient cash flows with lower risk scores and see which ones make the cut in the 31 resilient stocks with low risk scores. If value is your priority, scan for businesses trading below their assessed worth with solid fundamentals using the 35 high quality undervalued stocks. If you want to cast a wider net for less followed opportunities, broaden your research with the 19 high quality undiscovered gems.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Twist Bioscience might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681754110","isCrawlerRequest":true}